Milestone Pharmaceuticals Poised for Success with Cardamyst Approval and Strong Market Potential
I'm PortAI, I can summarize articles.
H.C. Wainwright analyst Brandon Folkes reiterated a Buy rating for Milestone Pharmaceuticals, setting a price target of $8.00, following the approval of Cardamyst for PSVT treatment. The approval enhances Milestone's commercial prospects, transitioning it to a commercial stage. Cardamyst's novel nasal spray targets an underserved market, with strong financial backing supporting its launch, indicating potential share momentum.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments